Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Akoya Biosciences initiated with an Overweight at Stephens » 16:27
10/05/22
10/05
16:27
10/05/22
16:27
AKYA

Akoya Biosciences

$12.66 /

+0.065 (+0.52%)

Stephens analyst Mason…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AKYA Akoya Biosciences
$12.66 /

+0.065 (+0.52%)

AKYA Akoya Biosciences
$12.66 /

+0.065 (+0.52%)

08/17/22 Piper Sandler
Akoya Biosciences price target raised to $17 from $14 at Piper Sandler
06/22/22 BTIG
Akoya Biosciences initiated with a Buy at BTIG
05/15/22 Piper Sandler
Akoya Biosciences price target lowered to $14 from $18 at Piper Sandler
04/13/22 Piper Sandler
Akoya not impacted from NanoString miss, says Piper Sandler
AKYA Akoya Biosciences
$12.66 /

+0.065 (+0.52%)

Hot Stocks
Aytu BioPharma announces continuing availability of Adzenys XR-ODT » 08:27
10/05/22
10/05
08:27
10/05/22
08:27
AYTU

Aytu BioPharma

/

+

Aytu BioPharma announced…

Aytu BioPharma announced the continuing availability of Adzenys XR-ODT extended-release orally disintegrating tablets, CII in response to numerous reported supply disruptions affecting generic Adderall XR extended-release capsule, CII for the treatment of attention deficit hyperactivity disorder. Adzenys XR-ODT is bioequivalent to Adderall XR and is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine. Adzenys XR-ODT is indicated for the treatment of ADHD in patients six years and older. Aytu BioPharma has maintained consistent Adzenys XR-ODT production levels at its Grand Prairie, Texas manufacturing facility to ensure ongoing supply of Adzenys XR-ODT and has experienced no supply disruptions to date. Adzenys XR-ODT has a twelve hour duration of action, has been FDA-approved as bioequivalent to Adderall XR, and is available in six equivalent strengths.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

07/21/22 H.C. Wainwright
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright
05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
  • 09
    Aug
Hot Stocks
Aytu BioPharma says its ADHD med available in response to Adderall shortage » 08:12
10/05/22
10/05
08:12
10/05/22
08:12
AYTU

Aytu BioPharma

/

+

Aytu BioPharma announced…

Aytu BioPharma announced the continuing availability of Adzenys XR-ODT extended-release orally disintegrating tablets, CII in response to numerous reported supply disruptions affecting generic Adderall XR extended-release capsule, CII for the treatment of attention deficit hyperactivity disorder or ADHD. Adzenys XR-ODT is bioequivalent to Adderall XR and is the only FDA-approved, extended-release, orally-disintegrating tablet formulation of amphetamine. Adzenys XR-ODT is indicated for the treatment of ADHD in patients six years and older Aytu BioPharma has maintained consistent Adzenys XR-ODT production levels at its Grand Prairie, Texas manufacturing facility to ensure ongoing supply of Adzenys XR-ODT and has experienced no supply disruptions to date.

ShowHide Related Items >><<
AYTU Aytu BioPharma
/

+

AYTU Aytu BioPharma
/

+

07/21/22 H.C. Wainwright
Aytu BioPharma price target lowered to $6 from $11 at H.C. Wainwright
05/17/22 Cantor Fitzgerald
Aytu BioPharma price target lowered to $5 from $11 at Cantor Fitzgerald
04/28/22 H.C. Wainwright
Aytu BioScience price target lowered to $11 from $24 at H.C. Wainwright
  • 09
    Aug
Recommendations
NuVasive price target lowered to $63 from $65 at Citi » 07:07
10/05/22
10/05
07:07
10/05/22
07:07
NUVA

NuVasive

$44.29 /

+0.31 (+0.70%)

Citi analyst Joanne…

Citi analyst Joanne Wuensch lowered the firm's price target on NuVasive to $63 from $65 and keeps a Buy rating on the shares. The analyst says entering the Q3 earnings cycle for medical supplies and technology, she balances macroeconomic headwinds with due diligence that indicates that while hospital staffing remains a headwind it is at least stable, and there are pockets of improved pricing. Wuensch is bullish on device utilization in a normalized environment and says "the best thing that could come out of the 3Q season is an in-line delivery, 2022 reiterations, and a level setting for 2023."

ShowHide Related Items >><<
NUVA NuVasive
$44.29 /

+0.31 (+0.70%)

NUVA NuVasive
$44.29 /

+0.31 (+0.70%)

09/30/22 Needham
NuVasive price target lowered to $53 from $67 at Needham
08/23/22 Piper Sandler
NuVasive selloff on bus tour comments an opportunity, says Piper Sandler
08/04/22 Canaccord
NuVasive price target raised to $55 from $50 at Canaccord
08/04/22 Piper Sandler
NuVasive price target lowered to $60 from $80 at Piper Sandler
NUVA NuVasive
$44.29 /

+0.31 (+0.70%)

Recommendations
iRhythm price target lowered to $147 from $157 at Citi » 07:06
10/05/22
10/05
07:06
10/05/22
07:06
IRTC

iRhythm

$134.58 /

+6.96 (+5.45%)

Citi analyst Joanne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IRTC iRhythm
$134.58 /

+6.96 (+5.45%)

IRTC iRhythm
$134.58 /

+6.96 (+5.45%)

09/28/22 JPMorgan
iRhythm should be bought after 25% pullback, says JPMorgan
09/22/22 JPMorgan
iRhythm price target raised to $190 from $185 at JPMorgan
09/12/22 JPMorgan
iRhythm analyst day to reaffirm bull thesis, says JPMorgan
09/02/22 Canaccord
iRhythm price target raised to $198 from $185 at Canaccord
IRTC iRhythm
$134.58 /

+6.96 (+5.45%)

IRTC iRhythm
$134.58 /

+6.96 (+5.45%)

Recommendations
Citi lowers Nevro target, opens 'negative catalyst watch' » 07:03
10/05/22
10/05
07:03
10/05/22
07:03
NVRO

Nevro

$49.29 /

+1.84 (+3.88%)

Citi analyst Joanne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NVRO Nevro
$49.29 /

+1.84 (+3.88%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

10/03/22 Piper Sandler
AACE guideline update positive for Nevro, says Piper Sandler
09/01/22 Piper Sandler
Piper stays on sidelines of Nevro despite 'handful of positive updates'
08/04/22 Piper Sandler
Nevro price target lowered to $45 from $64 at Piper Sandler
08/01/22 Piper Sandler
Nevro successfully defended exclusive SCS ability, says Piper Sandler
NVRO Nevro
$49.29 /

+1.84 (+3.88%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

Downgrade
Penumbra downgraded to Neutral from Buy at Citi » 06:58
10/05/22
10/05
06:58
10/05/22
06:58
PEN

Penumbra

/

+

Citi analyst Joanne…

Citi analyst Joanne Wuensch downgraded Penumbra to Neutral from Buy with a price target of $217, up from $170. The analyst cites valuation for the downgrade. She remains "enthusiastic" for Penumbra end markets and pipeline, but with a 57% upward move in the shares she's "pressed for valuation."

ShowHide Related Items >><<
PEN Penumbra
/

+

09/19/22 BTIG
Penumbra price target raised to $239 from $213 at BTIG
09/13/22 Truist
Penumbra price target raised to $230 from $180 at Truist
09/09/22 Needham
Penumbra upgraded to Buy at Needham on stronger growth and share gains
09/09/22 Needham
Penumbra upgraded to Buy from Hold at Needham
PEN Penumbra
/

+

PEN Penumbra
/

+

Recommendations
Sharecare price target lowered to $5 from $8 at BTIG » 06:25
10/05/22
10/05
06:25
10/05/22
06:25
SHCR

Sharecare

$2.04 /

+0.03 (+1.50%)

BTIG analyst David Larsen…

BTIG analyst David Larsen lowered the firm's price target on Sharecare to $5 from $8 to reflect broader market volatility but keeps a Buy rating on the shares after attending several conferences where incremental data has been disclosed on the performance of the business. The analyst is positive on Sharecare's "proven" management team, adding that there are many potential buyers of the Provider, Consumer, and possibly the Enterprise businesses that may be spun off. Larsen adds that he also likes Sharecare's significant in-sell opportunities with respect to additional products, sites, and members across the three divisions.

ShowHide Related Items >><<
SHCR Sharecare
$2.04 /

+0.03 (+1.50%)

SHCR Sharecare
$2.04 /

+0.03 (+1.50%)

08/30/22 Morgan Stanley
Morgan Stanley says Sharecare may be worth $3.25 per share on sum of parts basis
08/19/22 Canaccord
Sharecare price target lowered to $4 from $5 at Canaccord
07/20/22 Morgan Stanley
Sharecare initiated with an Equal Weight at Morgan Stanley
04/22/22 BTIG
BTIG remains positive on Sharecare after investor meetings
SHCR Sharecare
$2.04 /

+0.03 (+1.50%)

Hot Stocks
Virgin Orbit announces latest rocket ready for flight » 05:11
10/05/22
10/05
05:11
10/05/22
05:11
VORB

Virgin Orbit

$3.20 /

+0.13 (+4.23%)

Virgin Orbit announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VORB Virgin Orbit
$3.20 /

+0.13 (+4.23%)

VORB Virgin Orbit
$3.20 /

+0.13 (+4.23%)

06/28/22 Canaccord
Virgin Orbit's Brazil approval demonstrates solid execution, says Canaccord
05/12/22 Canaccord
Virgin Orbit price target lowered to $12 from $20 at Canaccord
02/28/22 Canaccord
Canaccord starts Virgin Orbit at Buy, sees 'exceptional market opportunity'
02/28/22 Canaccord
Virgin Orbit initiated with a Buy at Canaccord
VORB Virgin Orbit
$3.20 /

+0.13 (+4.23%)

Yesterday
On The Fly
Fly Intel: After-Hours Movers » 17:59
10/04/22
10/04
17:59
10/04/22
17:59
SAR

Saratoga Investment

$21.80 /

+0.88 (+4.21%)

, EMR

Emerson Electric

$78.21 /

+2.685 (+3.56%)

, BX

Blackstone

$93.52 /

+7.08 (+8.19%)

, GOGL

Golden Ocean

$8.17 /

+0.415 (+5.35%)

, YEXT

Yext

$4.77 /

+0.34 (+7.67%)

, ICVX

Icosavax

$3.21 /

+0.13 (+4.22%)

, SGH

SGH

$17.00 /

+0.97 (+6.05%)

, KORE

Kore Group

$2.23 /

+0.21 (+10.40%)

, NVRO

Nevro

$49.29 /

+1.84 (+3.88%)

, BRSP

BrightSpire Capital

$6.96 /

+0.54 (+8.41%)

, AMLX

Amylyx

$31.12 /

+1.4 (+4.71%)

Check out this evening's…

ShowHide Related Items >><<
YEXT Yext
$4.77 /

+0.34 (+7.67%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

SAR Saratoga Investment
$21.80 /

+0.88 (+4.21%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

KORE Kore Group
$2.23 /

+0.21 (+10.40%)

ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

BRSP BrightSpire Capital
$6.96 /

+0.54 (+8.41%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

SAR Saratoga Investment
$21.80 /

+0.88 (+4.21%)

10/07/21 B. Riley
Saratoga Investment price target raised to $31 from $30 at B. Riley
EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

10/03/22 Barclays
Emerson Electric price target lowered to $80 from $82 at Barclays
09/12/22 Citi
Citi opens 'positive Catalyst Watch' on MasTec, Emerson Electric
08/16/22 Wolfe Research
Aspen Technology initiated with a Peer Perform at Wolfe Research
08/16/22 Bernstein
Emerson Electric assumed with a Market Perform at Bernstein
BX Blackstone
$93.52 /

+7.08 (+8.19%)

08/31/22 Barclays
Blackstone initiated with an Overweight at Barclays
08/12/22 Deutsche Bank
Blackstone price target raised to $153 from $147 at Deutsche Bank
07/25/22 Piper Sandler
Blackstone price target lowered to $120 from $154 at Piper Sandler
07/24/22 Keefe Bruyette
Blackstone downgraded to Market Perform from Outperform at Keefe Bruyette
GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

09/26/22 Jefferies
Golden Ocean downgraded to Hold from Buy at Jefferies
07/20/22 Jefferies
Golden Ocean initiated with a Buy at Jefferies
05/20/22 Kepler Cheuvreux
Golden Ocean downgraded to Hold from Buy at Kepler Cheuvreux
05/20/22 H.C. Wainwright
Golden Ocean price target raised to $18 from $13 at H.C. Wainwright
YEXT Yext
$4.77 /

+0.34 (+7.67%)

09/08/22 MKM Partners
Yext price target lowered to $6 from $8 at MKM Partners
03/10/22 MKM Partners
Yext price target lowered to $8 from $17 at MKM Partners
03/09/22 DA Davidson
Yext downgraded to Neutral from Buy at DA Davidson
03/09/22 Needham
Yext downgraded to Hold from Buy at Needham
ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

06/29/22 Evercore ISI
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
06/29/22 Evercore ISI
Icosavax upgraded to Outperform from In Line at Evercore ISI
03/25/22 Evercore ISI
Evercore downgrades Icosavax amid 60% selloff after 'big error'
03/25/22 Evercore ISI
Icosavax downgraded to In Line from Outperform at Evercore ISI
SGH SGH
$17.00 /

+0.97 (+6.05%)

06/30/22 Needham
SGH price target lowered to $40 from $45 at Needham
06/30/22 Stifel
SGH price target lowered to $32 from $45 at Stifel
06/30/22 Deutsche Bank
SGH price target lowered to $32 from $40 at Deutsche Bank
06/30/22 Barclays
SGH price target lowered to $22 from $30 at Barclays
KORE Kore Group
$2.23 /

+0.21 (+10.40%)

08/12/22 Cowen
Kore Group price target lowered to $9 from $12.50 at Cowen
05/17/22 Deutsche Bank
Kore Group price target lowered to $6 from $7.50 at Deutsche Bank
04/12/22 Morgan Stanley
Kore Group price target lowered to $6.50 from $7.50 at Morgan Stanley
04/12/22 Morgan Stanley
Morgan Stanley cuts Telecom & Networking Equipment industry view to Cautious
NVRO Nevro
$49.29 /

+1.84 (+3.88%)

10/03/22 Piper Sandler
AACE guideline update positive for Nevro, says Piper Sandler
09/01/22 Piper Sandler
Piper stays on sidelines of Nevro despite 'handful of positive updates'
08/04/22 Piper Sandler
Nevro price target lowered to $45 from $64 at Piper Sandler
08/01/22 Piper Sandler
Nevro successfully defended exclusive SCS ability, says Piper Sandler
BRSP BrightSpire Capital
$6.96 /

+0.54 (+8.41%)

03/11/22 BTIG
BrightSpire Capital coverage transferred at BTIG
02/18/22 BofA
BrightSpire Capital initiated with a Neutral at BofA
01/04/22 B. Riley
BrightSpire Capital shares can return 35%, says at B. Riley
12/17/21 JMP Securities
BrightSpire Capital initiated with an Outperform at JMP Securities
AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

10/03/22 Citi
Citi ups Amylyx target, sees buying opportunity after selloff
09/08/22 SVB Securities
Amylyx price target raised to $50 from $31 at SVB Securities
09/08/22 Citi
Amylyx shares should rally $20 or more today, says Citi
07/06/22 Citi
Amylyx price target raised to $37 from $33 at Citi
YEXT Yext
$4.77 /

+0.34 (+7.67%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

SAR Saratoga Investment
$21.80 /

+0.88 (+4.21%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

KORE Kore Group
$2.23 /

+0.21 (+10.40%)

ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

BRSP BrightSpire Capital
$6.96 /

+0.54 (+8.41%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

  • 07
    Jan
  • 08
    Dec
EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

YEXT Yext
$4.77 /

+0.34 (+7.67%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

NVRO Nevro
$49.29 /

+1.84 (+3.88%)

ICVX Icosavax
$3.21 /

+0.13 (+4.22%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

EMR Emerson Electric
$78.21 /

+2.685 (+3.56%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

SGH SGH
$17.00 /

+0.97 (+6.05%)

GOGL Golden Ocean
$8.17 /

+0.415 (+5.35%)

BX Blackstone
$93.52 /

+7.08 (+8.19%)

AMLX Amylyx
$31.12 /

+1.4 (+4.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.